NCT03595371View on ClinicalTrials.gov

Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

May 29, 2018

Study Completion Date

May 29, 2018

Conditions
Schnitzler Syndrome
Interventions
DRUG

dapansutrile

500 mg dapansutrile administered twice daily (with a potential to increase the dosage to 2 g dapansutrile daily) for a duration of up to 14 consecutive days.

Trial Locations (1)

6525 GA

Radboudumc, Nijmegen

Sponsors
All Listed Sponsors
collaborator

Radboud University Medical Center

OTHER

lead

Olatec Therapeutics LLC

INDUSTRY

NCT03595371 - Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome | Biotech Hunter | Biotech Hunter